The PathCare molecular laboratory is pleased to announce a new in-house NGS assay designed to have specific relevance in targeted therapy for ovarian, breast, prostate and pancreatic carcinoma.
This assay is named the BRCAPlus assay and is designed to sequence the following genes:
HRR pathway genes: BRCA1, BRCA2, ATM, CHEK2, PALB2, BRIP1, BARD1, CDK12 (relevance for PARP inhibitor therapy)
PIK3CA : Relevance for PI3K/AKT/mTOR inhibitor therapy
TP53: Diagnostic and prognostic relevance in ovarian carcinoma
BRCAPlus Somatic NGS Panel